drugset
drugset / Trial / NCT01719549

Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1

NCT01719549 ↗

Phase 2 Completed 19 enrolled Asan Medical Center Novartis · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a single-center, prospective, single-arm, open-label phase II study

Timeline

Start
2012-09
Primary completion
2016-02
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Dovitinib Small molecule 500 mg Oral

Indications

gastric cancer